Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EPS (Weighted Average and Diluted) (2020 - 2025)

RxSight (RXST) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.22 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 46.67% year-over-year to -$0.22, compared with a TTM value of -$0.95 through Dec 2025, down 31.94%, and an annual FY2025 reading of -$0.95, down 33.8% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.22 for Q4 2025 at RxSight, up from -$0.24 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.09 in Q4 2021 and bottomed at -$3.53 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.51, with a median of -$0.29 recorded in 2025.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 82.72% in 2022, while the deepest fall reached 711.11% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.09 in 2021, then plummeted by 711.11% to -$0.55 in 2022, then surged by 54.55% to -$0.25 in 2023, then soared by 40.0% to -$0.15 in 2024, then plummeted by 46.67% to -$0.22 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RXST at -$0.22 in Q4 2025, -$0.24 in Q3 2025, and -$0.29 in Q2 2025.